Quali-quantitative synthesis of the global panorama of clinical trials on leprosy

Detalhes bibliográficos
Autor(a) principal: Meneghin, Rogério Almeida
Data de Publicação: 2023
Outros Autores: Frade, Marco Andrey Cipriani, Cohen, Mirian Miranda, de Oliveira e Dias, Ana Elisa Xavier, Longa, Leila Costa Duarte
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Health Review
Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183
Resumo: The work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil.
id BJRH-0_96c11e3f2ebe4af180a27090feb75ef2
oai_identifier_str oai:ojs2.ojs.brazilianjournals.com.br:article/59183
network_acronym_str BJRH-0
network_name_str Brazilian Journal of Health Review
repository_id_str
spelling Quali-quantitative synthesis of the global panorama of clinical trials on leprosyleprosyclinical trialThe work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil.Brazilian Journals Publicações de Periódicos e Editora Ltda.2023-04-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/5918310.34119/bjhrv6n2-300Brazilian Journal of Health Review; Vol. 6 No. 2 (2023); 8200-8223Brazilian Journal of Health Review; Vol. 6 Núm. 2 (2023); 8200-8223Brazilian Journal of Health Review; v. 6 n. 2 (2023); 8200-82232595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHenghttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183/42916Meneghin, Rogério AlmeidaFrade, Marco Andrey CiprianiCohen, Mirian Mirandade Oliveira e Dias, Ana Elisa XavierLonga, Leila Costa Duarteinfo:eu-repo/semantics/openAccess2023-04-26T17:39:56Zoai:ojs2.ojs.brazilianjournals.com.br:article/59183Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2023-04-26T17:39:56Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false
dc.title.none.fl_str_mv Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
title Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
spellingShingle Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
Meneghin, Rogério Almeida
leprosy
clinical trial
title_short Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
title_full Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
title_fullStr Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
title_full_unstemmed Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
title_sort Quali-quantitative synthesis of the global panorama of clinical trials on leprosy
author Meneghin, Rogério Almeida
author_facet Meneghin, Rogério Almeida
Frade, Marco Andrey Cipriani
Cohen, Mirian Miranda
de Oliveira e Dias, Ana Elisa Xavier
Longa, Leila Costa Duarte
author_role author
author2 Frade, Marco Andrey Cipriani
Cohen, Mirian Miranda
de Oliveira e Dias, Ana Elisa Xavier
Longa, Leila Costa Duarte
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Meneghin, Rogério Almeida
Frade, Marco Andrey Cipriani
Cohen, Mirian Miranda
de Oliveira e Dias, Ana Elisa Xavier
Longa, Leila Costa Duarte
dc.subject.por.fl_str_mv leprosy
clinical trial
topic leprosy
clinical trial
description The work presents the analysis and synthesis of clinical trials about leprosy worldwide in the last 20 years. Three technological aspects for study were defined, namely: diagnosis, drug/treatment and vaccine. Seventy-one (71) clinical trials were identified (11 for diagnosis, 54 for drug and 6 for vaccine), distributed among 62 main sponsors, 70 secondary sponsors and 21 countries, with 14 countries participating in 7 international consortia. For the recovery of clinical trials, the ICTRP® platform of the World Health Organization was used. Through quantitative and qualitative analysis and synthesis, a pattern of similarity was observed between 6 types of indicators highlighted in the figurative elements of the article. Eighteen types of final results (3 genera and 18 species) and 9 phases of clinical development were mapped. The most significant participation of non-hegemonic nations was found, which corroborates and validates the state of the art on the investment dedicated to the diseases of neglected populations. A temporal prospecting of two decades was adopted, although records were only identified in 15 years. In this time cut, 9 inflection points were identified, which demonstrates an oscillating development agenda, which presupposes an inconstant interest of the hegemonic pharmaceutical industry in favor of the struggle against leprosy that devastate neglected populations. It is concluded that the clinical effort aimed at leprosy is "corrective", because "treatment" has the most significant amount of clinical trials, and in the background is the "preventive" clinical effort, which represent the subquantities related to the categories "vaccine” and “diagnosis”. Therefore, it appears that the quali-quantitative analysis and synthesis allows us to assert that the clinical development scenario dedicated to leprosy deserves special attention from the State and other real factors of power, in order to create more effective public policies in favor of the neglected populations affected by leprosy. In summary, it is suggested that new public policies shall be created to encourage synergy between clinical trials, both national and international, in order to induce a safe path to clinical-therapeutic independence and, consequently, better performance in the struggle against leprosy in Brazil.
publishDate 2023
dc.date.none.fl_str_mv 2023-04-26
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183
10.34119/bjhrv6n2-300
url https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183
identifier_str_mv 10.34119/bjhrv6n2-300
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/59183/42916
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
dc.source.none.fl_str_mv Brazilian Journal of Health Review; Vol. 6 No. 2 (2023); 8200-8223
Brazilian Journal of Health Review; Vol. 6 Núm. 2 (2023); 8200-8223
Brazilian Journal of Health Review; v. 6 n. 2 (2023); 8200-8223
2595-6825
reponame:Brazilian Journal of Health Review
instname:Federação das Indústrias do Estado do Paraná (FIEP)
instacron:BJRH
instname_str Federação das Indústrias do Estado do Paraná (FIEP)
instacron_str BJRH
institution BJRH
reponame_str Brazilian Journal of Health Review
collection Brazilian Journal of Health Review
repository.name.fl_str_mv Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)
repository.mail.fl_str_mv || brazilianjhr@gmail.com
_version_ 1797240028937584640